Pericyazine 2.5mg tablets

Country: United Kingdom

Language: English

Source: MHRA (Medicines & Healthcare Products Regulatory Agency)

Active ingredient:

Pericyazine

Available from:

Mawdsley-Brooks & Company Ltd

ATC code:

N05AC01

INN (International Name):

Pericyazine

Dosage:

2.5mg

Pharmaceutical form:

Oral tablet

Administration route:

Oral

Class:

No Controlled Drug Status

Prescription type:

Valid as a prescribable product

Product summary:

BNF: 04020100

Patient Information leaflet

-1-
PACKAGE LEAFLET:
INFORMATION FOR THE PATIENT
PERICYAZINE 2.5MG TABLETS
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU
START TAKING THIS MEDICINE BECAUSE IT
CONTAINS INFORMATION IMPORTANT FOR YOU.
•
Keep this leaflet. You may need to read it
again
•
If you have any further questions, ask your
doctor or pharmacist
•
This medicine has been prescribed for you. Do
not pass it on to others. It may harm them, even
if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor
or pharmacist. This includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1. What pericyazine is and what it is used for
2. What you need to know before you take
pericyazine
3. How to take pericyazine
4. Possible side effects
5. How to store pericyazine
6. Contents of the pack and other information
1. WHAT PERICYAZINE IS AND WHAT IT IS
USED FOR
The name of your medicine is Pericyazine 2.5mg
Tablets (referred to as pericyazine throughout
this leaflet).This belongs to a group of medicines
called ‘phenothiazines’. It works by blocking
the effect of a chemical in the brain. It can be
used for:
•
Schizophrenia
•
The short term treatment of anxiety, agitation
and violent or dangerously impulsive
behaviour when used with other medicines
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE
PERICYAZINE
DO NOT TAKE THIS MEDICINE AND TELL
YOUR DOCTOR IF:
±You are allergic (hypersensitive) to
pericyazine or any of the other ingredients
in this medicine (listed in Section 6)
±Signs of an allergic reaction include: a rash,
swallowing or breathing problems, swelling
of your lips, face, throat or tongue
±You are pregnant, might become pregnant
or think you may be pregnant (see Section
below: ‘Pregnancy and breast-feeding’)
Do not take this medicine if any of the above
apply to you. If you are not sure, talk to your
doctor or pharmacist before taking pericyazine.
WARNINGS AND PRECAUTIONS
TALK TO YOUR DOCTOR OR PHARMACIST BEFORE
YOU TAKE THIS MEDICINE IF:
SYou hav

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS
1
NAME OF THE MEDICINAL PRODUCT
Pericyazine 2.5mg Tablets
2
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 2.5mg pericyazine.
For the full list of excipients, see section 6.1.
3
PHARMACEUTICAL FORM
Pericyazine 2.5mg Tablets: Circular, very pale lime-yellow tablet,
with one
face impressed ‘S171’ just inside the perimeter. Break-line on
reverse.
4
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
a)
In adults with schizophrenia or other psychoses, for the treatment of
symptoms or prevention of relapse.
b)
In anxiety, psychomotor agitation, violent or dangerously impulsive
behaviour. Pericyazine is used as an adjunct to the short-term
management of
these conditions.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
_ Severe conditions _
_Indication (a) _
_ _
Adults:_ _Initially 75 mg per day in divided doses. Dosage should be
increased
by 25 mg per day at weekly intervals until the optimum effect is
achieved.
Maintenance therapy would not normally be expected to exceed 300 mg
per
day.
Elderly: _ _Initially 15-30 mg per day in divided doses. If this is
well tolerated
the dosage may be increased if necessary for optimum control of
behaviour.
_Mild or moderate conditions _
_ _
_Indication (b) _
_ _
Adults: Initially 15-30 mg daily, divided into two portions with a
larger dose
being given in the evening.
Elderly: 5-10 mg per day is suggested as a starting dose. It may be
divided so
that a larger portion is given in the evening. Half or quarter the
normal adult
dose may be sufficient for maintenance therapy.
Pericyazine tablets are not recommended for children.
Method of administration
Oral.
Dosage requirement varies with the individual and the severity of the
condition being treated. Initial dosage should be low with progressive
increases until the desired response is obtained, after which dosage
should be
adjusted to maintain control of the symptoms.
4.3
CONTRAINDICATIONS
See use in pregnancy below. Known hypersensitivity to pericyazine or
to any
of the other excipi